Janux Therapeutics, Inc. (NASDAQ:JANX) Receives $66.29 Consensus Target Price from Analysts

Janux Therapeutics, Inc. (NASDAQ:JANXGet Free Report) has been given an average recommendation of “Moderate Buy” by the eight brokerages that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $66.29.

JANX has been the topic of a number of recent research reports. BTIG Research initiated coverage on Janux Therapeutics in a research report on Thursday, March 21st. They issued a “buy” rating and a $62.00 target price on the stock. Scotiabank initiated coverage on Janux Therapeutics in a research report on Thursday, May 30th. They issued a “sector perform” rating and a $47.00 target price on the stock. Bank of America lifted their target price on Janux Therapeutics from $24.00 to $48.00 and gave the company a “buy” rating in a research report on Wednesday, March 13th. HC Wainwright lifted their target price on Janux Therapeutics from $50.00 to $63.00 and gave the company a “buy” rating in a research report on Monday, May 13th. Finally, Wedbush lifted their target price on Janux Therapeutics from $53.00 to $74.00 and gave the company an “outperform” rating in a research report on Wednesday, May 8th.

Check Out Our Latest Stock Report on Janux Therapeutics

Janux Therapeutics Price Performance

JANX opened at $42.59 on Tuesday. The business’s 50-day moving average price is $48.32 and its two-hundred day moving average price is $28.25. Janux Therapeutics has a 1 year low of $5.65 and a 1 year high of $65.60. The company has a market capitalization of $2.21 billion, a price-to-earnings ratio of -34.91 and a beta of 3.71.

Janux Therapeutics (NASDAQ:JANXGet Free Report) last released its quarterly earnings results on Tuesday, May 7th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.05. The firm had revenue of $1.25 million for the quarter, compared to the consensus estimate of $0.98 million. Janux Therapeutics had a negative return on equity of 13.49% and a negative net margin of 762.92%. Sell-side analysts anticipate that Janux Therapeutics will post -1.34 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Janux Therapeutics news, CFO Tighe Reardon sold 822,721 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $54.75, for a total transaction of $45,043,974.75. Following the transaction, the chief financial officer now owns 633,673 shares of the company’s stock, valued at $34,693,596.75. The sale was disclosed in a document filed with the SEC, which is available through this link. In other news, major shareholder Ventures Xi L.P. Avalon sold 677,279 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $54.75, for a total transaction of $37,081,025.25. Following the completion of the sale, the insider now owns 3,271,216 shares in the company, valued at $179,099,076. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Tighe Reardon sold 822,721 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $54.75, for a total value of $45,043,974.75. Following the sale, the chief financial officer now owns 633,673 shares of the company’s stock, valued at approximately $34,693,596.75. The disclosure for this sale can be found here. Insiders have sold a total of 3,000,000 shares of company stock valued at $164,250,000 over the last 90 days. 35.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Janux Therapeutics

A number of institutional investors have recently made changes to their positions in JANX. Barclays PLC boosted its holdings in shares of Janux Therapeutics by 227.1% during the third quarter. Barclays PLC now owns 17,922 shares of the company’s stock worth $181,000 after acquiring an additional 12,443 shares during the period. FMR LLC boosted its stake in shares of Janux Therapeutics by 25.5% in the third quarter. FMR LLC now owns 6,351,322 shares of the company’s stock valued at $64,021,000 after buying an additional 1,288,526 shares during the period. Old Well Partners LLC bought a new stake in shares of Janux Therapeutics in the third quarter valued at approximately $104,000. Corton Capital Inc. bought a new stake in shares of Janux Therapeutics in the third quarter valued at approximately $111,000. Finally, Adage Capital Partners GP L.L.C. boosted its stake in shares of Janux Therapeutics by 27.8% in the third quarter. Adage Capital Partners GP L.L.C. now owns 1,150,000 shares of the company’s stock valued at $11,592,000 after buying an additional 250,000 shares during the period. Institutional investors own 75.39% of the company’s stock.

About Janux Therapeutics

(Get Free Report

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.

Featured Articles

Analyst Recommendations for Janux Therapeutics (NASDAQ:JANX)

Receive News & Ratings for Janux Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Janux Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.